Treatment options for laryngeal carcinoma, one of the most common head and neck malignancies, consist of radiotherapy, surgery, chemotherapy or a combination thereof. The functional treatment of laryngeal carcinoma poses a considerable challenge because of its resistance to chemotherapy and radiotherapy, and its tendency for local recurrence. Finding ways to inhibit the energy supply of malignant tumours is becoming an increasingly attractive proposition. Glucose transporter-1 (Glut-1; encoded by the SLC2A1 gene in humans) is the main transporter of glucose in solid carcinomas and has become a focus of cancer research. Recently, it was shown that the increased expression of SLC2A1 in head and neck carcinomas is correlated with lymph node metastasis, poor survival and clinical stage, and revealed that the suppression of SLC2A1 expression by antisense oligodeoxynucleotides decreased glucose uptake and inhibited the proliferation of Hep-2 cells. Thus, the authors propose the suppression of SLC2A1 expression as a new therapeutic target for laryngeal carcinoma.
WarburgO: On the origin of cancer cells. Science1956; 123: 309–314.
2.
NijstenMWvan DamGM: Hypothesis: Using the Warburg effect against cancer by reducing glucose and providing lactate. Med Hypotheses2009; 73: 48–51.
3.
WahlHDaudiSKshirsagarM: Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol Oncol2010; 116: 21–27.
4.
RobeyIFStephenRMBrownKS: Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia2008; 10: 745–756.
5.
BuskMHorsmanMRKristjansenPE: Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer2008; 122: 2726–2734.
6.
GilliesRJGatenbyRA: Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis?. J Bioenerg Biomembr2007; 39: 251–257.
7.
LiLFZhouSHZhaoK: Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm2008; 23: 701–714.
8.
TianMZhangHNakasoneY: Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging2004; 31: 5–12.
9.
de Geus-OeiLFvan KriekenJHAliredjoRP: Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer2007; 55: 79–87.
10.
KurokawaTYoshidaYKawaharaK: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer2004; 109: 926–932.
11.
YenTCSeeLCLaiCH: 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med2004; 45: 22–29.
12.
KhandaniAHDunphyCHMeteesatienP: Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun2009; 30: 594–601.
13.
PaudyalBPaudyalPOriuchiN: Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol2008; 33: 1047–1054.
14.
HigashiTTamakiNHondaT: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med1997; 38: 1337–1344.
15.
BrownRSLeungJYFisherSJ: Intratumoral distribution of tritiated-FDG in breast carcinoma: Correlation between Glut-1 expression and FDG uptake. J Nucl Med1996; 37: 1042–1047.
16.
WoodISTrayhurnP: Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br J Nutr2003; 89: 3–9.
17.
Rivenzon-SegalDRushkinEPolak-CharconS: Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab2000; 279: E508–E519.
18.
AmannTHellerbrandC: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets2009; 13: 1411–1427.
19.
PessinJEBellGI: Mammalian facilitative glucose transporter family: Structure and molecular regulation. Annu Rev Physiol1992; 54: 911–930.
20.
StokkelMPLinthorstMFBormJJ: A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Cancer Res Clin Oncol2002; 128: 393–399.
21.
NoguchiYSaitoAMiyagiY: Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett2000; 154: 175–182.
22.
KawamuraTKusakabeTSuginoT: Expression of glucose transporter-1 in human gastric carcinoma: Association with tumor aggressiveness, metastasis, and patient survival. Cancer2001; 92: 634–641.
23.
HigashiTSagaTNakamotoY: Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med2002; 43: 173–180.
24.
HigashiKUedaYSakuraiA: Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancerEur J Nucl Med2000; 27: 1778–1785.
25.
AmannTMaegdefrauUHartmannA: GLUT1 expression is increased in hepato cellular carcinoma and promotes tumori genesis. Am J Pathol2009; 174: 1544–1552.
26.
DemasiAPCostaAFAltemaniA: Glucose transporter protein 1 expression in mucoepidermoid carcinoma of salivary gland: Correlation with grade of malignancy. Int J Exp Pathol2010; 91: 107–113.
ParentePColiAMassiG: Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res2008; 27: 34.
29.
AhrensWARidenourRV3rdCaronBL: GLUT-1 expression in mesenchymal tumors: An immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol2008; 39: 1519–1526.
30.
EndoMTateishiUSekiK: Prognostic implications of glucose transporter protein-1 (Glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol2007; 37: 955–960.
31.
EckertAWLautnerMHTaubertH: Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep2008; 20: 1381–1385.
32.
LeganMLuzarBMaroltVF: Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol2009; 44: 1101–1108.
33.
ZhouSWangSWuQ: Expression of glucose transporter-1 and −3 in the head and neck carcinoma–the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec2008; 70: 189–194.
34.
FarhadiehRDReesCGYangJL: Radiotherapy in larynx squamous cell carcinoma is not associated with an increased diagnosis of second primary tumours. Clin Oncol (R Coll Radiol)2009; 21: 315–319.
35.
SchrijversMLvan der LaanBFde BockGH: Overexpression of intrinsic hypoxia markers HIF1α and CA-IX predict for local recurrence in stage T1–T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys2008; 72: 161–169.
36.
CikojevićDGluncićIKlancnikM: Cigarette smoking and progression of laryngeal lesions. Coll Antropol2010; 34 (suppl 1): 45–48.
37.
TaiPYuEShielsR: Long-term survival rates of laryngeal cancer patients treated by radiation and surgery, radiation alone, and surgery alone: Studied by lognormal and Kaplan–Meier survival methods. BMC Cancer2005; 5: 13.
38.
GhaffarSIkramMImamSZ: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak2010; 20: 171–174.
39.
VargheseBTSebastianPMathewA: Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: A follow-up study. Acta Otolaryngol2009; 129: 1480–1485.
40.
BajajYShayahASethiN: Clinical outcomes of total laryngectomy for laryngeal carcinoma. Kathmandu Univ Med J (KUMJ)2009; 7: 258–262.
41.
MahlerVBoysenMBrøndboK: Radiotherapy or CO2 laser surgery as treatment of T1a glottic carcinoma?. Eur Arch Otorhinolaryngol2010; 267: 743–750.
42.
TunaBKatilmişHOztürkcanS: Outcome of conservation surgery for laryngeal carcinoma: An 8-year trial. Eur Arch Otorhinolaryngol2009; 266: 1681–1686.
43.
JemalASiegelRWardE: Cancer statistics, 2006. CA Cancer J Clin2006; 56: 106–130.
44.
JohansenLVGrauCOvergaardJ: Supraglottic carcinoma: Patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. Int J Radiat Oncol Biol Phys2002; 53: 948–958.
LouwLClaassenJ: Rationale for adjuvant fatty acid therapy to prevent radiotherapy failure and tumor recurrence during early laryngeal squamous cell carcinoma. Prostaglandins Leukot Essent Fatty Acids2008; 78: 21–26.
47.
XuRHPelicanoHZhouY: Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res2005; 65: 613–621.
48.
ZhouSHFanJChenXM: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck2009; 31: 1624–1633.
49.
De SchutterHLanduytWVerbekenE: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy. BMC Cancer2005; 5: 42.
50.
ChanJYChuACFungKP: Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA. Life Sci2000; 67: 2117–2124.
51.
ChenCPLiXXZhangLR: Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 cells. Bioconjug Chem2002; 13: 525–529.
52.
ItoSFukusatoTNemotoT: Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst2002; 94: 1080–1091.
53.
ChanJYKongSKChoyYM: Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci1999; 65: 63–70.
54.
ChoiJWYoonDJLeeHW: Antisense GLUT1 RNA suppresses the transforming phenotypes of NIH 3T3 cells transformed by N-Ras. Yonsei Med J1995; 36: 480–486.
55.
SamihNHovsepianSAouaniA: Glut-1 translocation in FRTL-5 thyroid cells: Role of phosphatidylinositol 3-kinase and N-glycosylation. Endocrinology2000; 141: 4146–4155.
56.
MelstromLGSalabatMRDingXZ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas2008; 37: 426–431.
57.
GranvilleCAMemmottRMGillsJJ: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res2006; 12: 679–689.
58.
WangWXuGLJiaWD: Expression and correlation of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res2009; 37: 417–425.
59.
McCartyMFBarroso-ArandaJContrerasF: Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses2010; 74: 789–797.
60.
SeeberLMZweemerRPVerheijenRH: Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int2010; 2010: 580971.
61.
SeagrovesTNRyanHELuH: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol2001; 21: 3436–3444.
62.
OganeNYasudaMShimizuM: Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol2010; 14: 23–29.
63.
EvansABatesVTroyH: Glut-1 as a therapeutic target: Increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol2008; 61: 377–393.
64.
KamlahFEulBGLiS: Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther2009; 16: 195–205.
65.
KaplanONavonGLyonRC: Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res1990; 50: 544–551.
66.
AftRLZhangFWGiusD: Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell death. Br J Cancer2002; 87: 805–812.
67.
MaschekGSavarajNPriebeW: 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res2004; 64: 31–34.
68.
MaherJCSavarajNPriebeW: Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas2005; 30: e34–e39.
69.
SimonsALAhmadIMMattsonDM: 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res2007; 67: 3364–3370.
70.
PrasannaVKVenkataramanaNKDwarakanathBS: Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma. J Cancer Res Ther2009; 5 (suppl 1): S44–S47.
71.
GuptaSFarooqueAAdhikariJS: Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. J Cancer Res Ther2009; 5 (suppl 1): S16–S20.
72.
DwarakanathBSSinghDBanerjiAK: Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects. J Cancer Res Ther2009; 5 (suppl 1): S21–S26.
73.
FurutaEOkudaHKobayashiA: Metabolic genes in cancer: Their roles in tumor progression and clinical implications. Biochim Biophys Acta2010; 1805: 141–152.
74.
JasonTLBergRWVincentMD: Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: Effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs. Gene Expr2007; 13: 227–239.
75.
HunterAMLaCasseECKornelukRG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis2007; 12: 1543–1568.
76.
TschaharganehDEhemannVNussbaumT: Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathol Oncol Res2007; 13: 84–90.
77.
CastanottoDRossiJJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature2009; 457: 426–433.
78.
DeVincenzoJLambkin-WilliamsRWilkinsonT: A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA2010; 107: 8800–8805.
79.
ShenJSamulRSilvaRL: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther2006; 13: 225–234.
80.
FireAXuSMontgomeryMK: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature1998; 391: 806–811.
81.
RamanathanAWangCSchreiberSL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A2005; 102: 5992–5997.
82.
MachedaMLRogersSBestJD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol2005; 202: 654–662.
